


## IDMP Common Core Ontology

Info Package for the Cross-Industry Initiative

## IDMP Common Core Ontology: Creating interoperability by design

Work together with the IDMP Logical Model to achieve a FAIR semi-automatic implementation





ISO standards to ensure **patient** safety with unambiguous identification of medicinal products.



Facilitate implementation and automate connectivity with an agnostic data architecture.



Enable interoperability and connectivity across regulatory jurisdictions with a **FAIR implementation**.




#### IDMP Logical Model Requirements

UN COM

IDMP Logical Model shall be related to relevant business processes

- Definitions of elements linked to a single glossary of terms referenced by the conceptual model
- Describe the structure of and the relations between the data elements supporting exchange of information related to medicinal products
- **Specify** the data types for the data elements and cardinality of the relations between groups of data elements.
- Map to other logical data models
- Independent of any technology or implementation environment





### Project objectives and value proposition for the MVP


Demonstrate the added value of a common core ontology for the ISO IDMP standards to enable data usability on a wide scale and advance collaboration across organizational boundaries.

The MVP implementation is a prototypic approach to provide insight on how we may realize this value later with a comprehensive ontology for the pharmaceutical industry on a larger scale in a collaborative environment, starting with **substance** information.



### IDMP Common Core Ontology as the connecting bridge

**Advancing cross-functional collaboration:** Bridging different regional or functional perspectives on common substance-related data objects requires a well-defined common core ontology that connects the perspectives to global and scientifically objective representations.








## IDMP Common Core Ontology as the connecting bridge

**Advancing industry collaboration:** Bridging different industry players on common substance-related data objects requires a well-defined common core ontology that connects the perspectives to global and scientifically objective representations.





## Problem Statement: Diverging IDMP implementations are a risk

There is a risk that the diverging implementations lead to huge integration and interoperability costs.


- 1. Diverging implementation of IDMP across regions and jurisdictional domains.
- 2. Inconsistencies of interpretation by implementing organizations.
- 3. Missing semantic alignment between regulatory implementations.
- 4. Essential governance of the IDMP standards and implementations is not assigned to a specific overarching governing body.

© Pistoia Alliance

## IDMP Common Core Ontology for Global Implementation Approach

- ✓ Cross-industry collaboration with an iterative implementation approach
- ✓ Implementation of the ISO IDMP Logical Model with a FAIR ontological approach
- ✓ Enable the interoperability of data and metadata across the value chain
  - Support the automation of regulatory processes
  - Reduce mapping and governance strains
  - Support the unambiguous communication across jurisdictions





5 March, 2022

#### IDMP Common Core Ontology MVP

#### Why?


- 1. Current IDMP implementations are diverse / non-standardized on the key data objects
- 2. Opportunity: There is big interest in a FAIR implementation of the IDMP standard
- 3. Opportunity: There is pre-work so we don't start from scratch

#### What is critical for success?

- 1. Creation of a quality MVP release that is useful (implementable, actually used) for pharma companies and others.
- 2. Demonstration of the use and added value of the ontology to obtain post-MVP funding.
- 3. Demonstration of governance capabilities.
- 4. Open communication to all relevant stakeholders, making all results openly available.



#### Project setup for the MVP phase



 $\Leftrightarrow$ 

## Overview of target deliverables

ID	Deliverable
1	Project Organization, Stakeholder Management and Alignments
2	High-Level Overarching Story for Decision Makers (upfront)
3	Specification of use-cases, usage scenarios and competency questions
4	IDMP Common Core Ontology Model MVP: fit for use at pharma and authorities
5	Use-Case Data/Content Mapping: Pharma, GSRS, EUSRS
6	Use-Case Demonstrations: Unique Identification, Linking, Inference, WOW
7	Ontology Governance MVP: collaborative development, Ontology MVP release
8	Describe Value Capture: quantify and qualify the benefit of having an ontology

#### Use case structure for iterative implementation

#### 1. Unambiguous substance identification in Clinical context (Bayer, Merck, Novartis)

Scenario 1: Ingredient role mapping

Scenario 2: Registered products administered during clinical trials (Ingredient role "active")

#### 2. Governance in a collaborative environment

Include stakeholders and interested parties in decisions reflected in an agile manner in the ontology (e.g., WHO, ISO, FDA, EMA...).

3. Substance characteristics linked to safety profiles (GSK, ingredient role Adjuvant)

#### 4. Substance contaminants tracking - Nitrosamine (GSRS)


Scenario: ingredient role


Scenario: Governance decisions incorporated into ontology – FDA, EMA use cases



## Starting Data Domain: Substance

Substance-Product connection as bridge between different functions, e.g., Regulatory-Manufacturing







#### Milestones

M1: Consolidation of pre-work

M2: Demonstrations of prioritized usage scenarios on substance

M3: Demonstrations of collaborative governance framework

M4: MVP ontology release

# How to get involved? Contact Us!



#### **Gerhard Noelken**

Business Development Europe at Pistoia Alliance, Inc. Project Lead for IDMP Common Core Ontology gerhard.noelken@pistoiaalliance.org
<a href="https://www.pistoiaalliance.org/">https://www.pistoiaalliance.org/</a>